<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05066165</url>
  </required_header>
  <id_info>
    <org_study_id>ITL-5001-CL-001</org_study_id>
    <nct_id>NCT05066165</nct_id>
  </id_info>
  <brief_title>Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia</brief_title>
  <official_title>Phase 1/2a, Single Dose Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intellia Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intellia Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to evaluate the safety, tolerability, cellular kinetics (CK),&#xD;
      activity, and pharmacodynamics (PD) of NTLA-5001 in participants with Acute Myeloid Leukemia&#xD;
      (AML).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This 2-part first in human (FIH) study is comprised of two open-label arms. It is a&#xD;
      multi-center, Phase 1/2a study evaluating the safety and activity of NTLA-5001 in subjects&#xD;
      with persistent or recurrent Acute Myeloid Leukemia after first-line or later therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as determined by adverse events (AEs) and dose-limiting toxicities (DLTs) (dose escalation only)</measure>
    <time_frame>From NTLA-5001 infusion up to week 112 post-infusion, primary DLT assessment up to 28 days post-infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize cell kinetics of NTLA-5001 via frequency of NTLA 5001 T cell receptor (TCR) transgene copy</measure>
    <time_frame>From NTLA-5001 infusion up to 112 weeks post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize cell kinetics of NTLA-5001 via persistence of NTLA 5001 T cell receptor (TCR) transgene copy</measure>
    <time_frame>From NTLA-5001 infusion up to 112 weeks post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the antitumor activity of NTLA-5001 in participants with AML via tumor response</measure>
    <time_frame>From NTLA-5001 infusion up to 112 weeks post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the antitumor activity of NTLA-5001 in participants with AML via response duration</measure>
    <time_frame>From NTLA-5001 infusion up to 112 weeks post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the antitumor activity of NTLA-5001 in participants with AML via disease progression</measure>
    <time_frame>From NTLA-5001 infusion up to 112 weeks post-infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm 1: NTLA-5001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to three escalation cohorts in phase 1 followed by one expansion cohort in phase 2. Subjects have AML and bone marrow blast count &lt;5%, administered by IV infusion following lymphodepleting chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: NTLA-5001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to three escalation cohorts in phase 1 followed by one expansion cohort in phase 2. Subjects have AML and bone marrow blast count ≥5%, administered by IV infusion following lymphodepleting chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Arm 1: NTLA-5001</intervention_name>
    <description>Autologous WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9 as intravenous infusion after pre-conditioning chemotherapy.&#xD;
Cyclophosphamide and Fludarabine will be administered on Day -5, -4, and -3 as intravenous infusion.</description>
    <arm_group_label>Arm 1: NTLA-5001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Arm 2: NTLA-5001</intervention_name>
    <description>Autologous WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9 as intravenous infusion after pre-conditioning chemotherapy.&#xD;
Cyclophosphamide and Fludarabine will be administered on Day -5, -4, and -3 as intravenous infusion.</description>
    <arm_group_label>Arm 2: NTLA-5001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (abbreviated):&#xD;
&#xD;
          -  Has AML as defined by World Health Organization&#xD;
&#xD;
          -  Has detectable disease following first-line therapy&#xD;
&#xD;
          -  Is ≥ 18 years of age.&#xD;
&#xD;
          -  Carries the human leukocyte antigen-A0201 (HLA-A*02:01) allele.&#xD;
&#xD;
          -  Has ECOG performance status of 0 to 1.&#xD;
&#xD;
          -  Has adequate absolute total lymphocyte count&#xD;
&#xD;
          -  Has adequate cardiac, renal, and liver organ function&#xD;
&#xD;
        Exclusion Criteria (abbreviated):&#xD;
&#xD;
          -  Has received AML-directed therapy or immunomodulatory therapy within a specified&#xD;
             window prior to study entry.&#xD;
&#xD;
          -  Has received allogeneic hematopoietic cell transplant within 84 days, with ongoing&#xD;
             GVHD, with recent DLI, or on active immunosuppression.&#xD;
&#xD;
          -  Has CNS involvement by tumor.&#xD;
&#xD;
          -  Has severe autoimmunity requiring immunomodulatory therapy.&#xD;
&#xD;
          -  Has active disseminated intravascular coagulation (DIC), bleeding or coagulopathy.&#xD;
&#xD;
          -  Has leukocytosis ≥ 20,000 blasts/μL despite hydroxyurea or has rapidly progressive&#xD;
             disease&#xD;
&#xD;
          -  Has human immunodeficiency virus (HIV) infection, or any uncontrolled infection.&#xD;
&#xD;
          -  Female subjects are pregnant or breastfeeding; or are of childbearing potential and&#xD;
             are unwilling to use protocol specified method of contraception.&#xD;
&#xD;
          -  Male subjects who have female partners of childbearing potential and are unwilling to&#xD;
             use protocol specified method of contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Trial Manager at Intellia</last_name>
    <phone>833-888-0387</phone>
    <email>clinicalscience@intelliatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site 5</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 2</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 6</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 3</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 4</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 10</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 8</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 9</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 7</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NTLA-5001</keyword>
  <keyword>cell kinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>clustered regularly interspaced short palindromic repeats</keyword>
  <keyword>CRISPR</keyword>
  <keyword>AML</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>TCR T Cell Therapy</keyword>
  <keyword>Autologous</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Immunoproliferative Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

